» Articles » PMID: 38057663

N-methylpseudouridylation of MRNA Causes +1 Ribosomal Frameshifting

Abstract

In vitro-transcribed (IVT) mRNAs are modalities that can combat human disease, exemplified by their use as vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). IVT mRNAs are transfected into target cells, where they are translated into recombinant protein, and the biological activity or immunogenicity of the encoded protein exerts an intended therapeutic effect. Modified ribonucleotides are commonly incorporated into therapeutic IVT mRNAs to decrease their innate immunogenicity, but their effects on mRNA translation fidelity have not been fully explored. Here we demonstrate that incorporation of N-methylpseudouridine into mRNA results in +1 ribosomal frameshifting in vitro and that cellular immunity in mice and humans to +1 frameshifted products from BNT162b2 vaccine mRNA translation occurs after vaccination. The +1 ribosome frameshifting observed is probably a consequence of N-methylpseudouridine-induced ribosome stalling during IVT mRNA translation, with frameshifting occurring at ribosome slippery sequences. However, we demonstrate that synonymous targeting of such slippery sequences provides an effective strategy to reduce the production of frameshifted products. Overall, these data increase our understanding of how modified ribonucleotides affect the fidelity of mRNA translation, and although there are no adverse outcomes reported from mistranslation of mRNA-based SARS-CoV-2 vaccines in humans, these data highlight potential off-target effects for future mRNA-based therapeutics and demonstrate the requirement for sequence optimization.

Citing Articles

mRNA mA regulates gene expression via H3K4me3 shift in 5' UTR.

Yang Y, Huang Y, Wang T, Li S, Jiang J, Chen S Genome Biol. 2025; 26(1):54.

PMID: 40075435 PMC: 11900566. DOI: 10.1186/s13059-025-03515-8.


Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.


Epitranscriptomics in the Glioma Context: A Brief Overview.

Santamarina-Ojeda P, Fernandez A, Fraga M Cancers (Basel). 2025; 17(4).

PMID: 40002173 PMC: 11853273. DOI: 10.3390/cancers17040578.


Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection.

Stiving A, Roose B, Tubbs C, Haverick M, Gruber A, Rustandi R NPJ Vaccines. 2025; 10(1):38.

PMID: 39988579 PMC: 11847942. DOI: 10.1038/s41541-025-01082-4.


ZUGC-RNA degradation generates immunosuppressor to evade immune responses in eukaryotes.

Gao S, Chen M, Wich D, Bloomer H, Qu Z, Guan H bioRxiv. 2025; .

PMID: 39974952 PMC: 11838226. DOI: 10.1101/2025.01.27.633273.


References
1.
Hogan M, Pardi N . mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annu Rev Med. 2021; 73:17-39. DOI: 10.1146/annurev-med-042420-112725. View

2.
Chaudhary N, Weissman D, Whitehead K . mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021; 20(11):817-838. PMC: 8386155. DOI: 10.1038/s41573-021-00283-5. View

3.
Anderson B, Muramatsu H, Nallagatla S, Bevilacqua P, Sansing L, Weissman D . Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010; 38(17):5884-92. PMC: 2943593. DOI: 10.1093/nar/gkq347. View

4.
Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C . Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006; 108(13):4009-17. DOI: 10.1182/blood-2006-04-015024. View

5.
Andries O, Mc Cafferty S, De Smedt S, Weiss R, Sanders N, Kitada T . N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015; 217:337-44. DOI: 10.1016/j.jconrel.2015.08.051. View